Safety Study of OXi4503 (a Vascular Disrupting Agent) Given by 3 x Weekly Intravenous Infusions to Patients With Advanced Solid Tumors
Clinical trial NCT00977210 · COMPLETED
Trial details
- NCT number
- NCT00977210
- Sponsor
- Mateon Therapeutics
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2005-07-01
- Primary completion
- 2010-09-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.